期刊文献+

中药联合DA化疗方案治疗老年急性髓系白血病的疗效 被引量:7

Efficacy of combined use of Chinese medicine with DA chemotherapy regimen in treating senile patients with acute myelogenous leukemia
原文传递
导出
摘要 目的观察中药联合DA化疗方案治疗老年急性髓系白血病患者的疗效及安全性。方法老年急性髓系白血病患者86例分为两组:C组40例,予常规DA化疗方案(阿糖胞苷+柔红霉素)静脉滴注治疗;A组46例,加用益气健脾补肾汤内服治疗。比较化疗2个疗程的临床疗效、骨髓抑制及不良反应发生情况。结果 A、C组临床总有效率相仿(87.0%vs.82.5%)(P>0.05)。A组治疗1、7、14d时的Hb、WBC和Plt均低于C组(P<0.05)。A组不良反应发生率低于C组(P<0.05)。结论中药联合DA化疗方案治疗老年急性髓系白血病疗效较单用DA化疗方案好,不良反应少。 Objective To observe the efficacy and safety of combined use of Chinese medicine with DA chemotherapy regimen in treating senile patients with acute myelogenous leukemia(AML).Methods Eighty-six senile patients with AML were divided into two groups.Conventional DA(cytarabine+daunorubicin)chemotherapy regimen was performed in group C(40cases)and additional Yiqi Jianpi Bushen decoction was orally taken in group A(46cases).Clinical efficacy,myelosuppression and adverse effects after two cycles of chemotherapy were compared between two groups.Results Overall effectiveness rates of two groups were similar(87.0% vs.82.5%)(P〉0.05).Hb,WBC and Plt on the 1^st,7^th and 14^ th day during treatment were lower in group A than those in group C(P〈0.05).Adverse effect rate was lower in group A than that in group C(P〈0.05).Conclusion Chinese medicine combined with DA chemotherapy regimen has better efficacy and less adverse effects than DA chemotherapy regimen alone in treating senile patients with AML.
作者 刘珂
出处 《江苏医药》 CAS 2015年第4期410-412,共3页 Jiangsu Medical Journal
关键词 急性髓系白血病 DA化疗方案 老年 Acute myelogenous leukemia DA chemotherapy regimen Geriatrics
  • 相关文献

参考文献9

二级参考文献102

  • 1徐国宾,史晓敏.B型钠尿肽及N末端B型钠尿肽原在临床应用中值得关注的几个问题[J].中华检验医学杂志,2006,29(1):9-11. 被引量:71
  • 2邵彬,秦尤文,高彦荣,王椿,颜式可,蔡琦,姜杰玲,白海涛,赵旻.老年急性髓性白血病临床分析[J].中国老年学杂志,2006,26(6):834-836. 被引量:5
  • 3薛萌,陈宝安,邵泽叶,高冲,王骏,陈坚,丁家华,孙耘玉,高峰,马燕,赵刚.羟基喜树碱诱导人骨髓增生异常综合征细胞系MUTZ-1细胞凋亡及机制的研究[J].中华血液学杂志,2007,28(5):344-345. 被引量:7
  • 4Vardiman J W, Thiele J, Arber D A, et al. The 2008 revision of the World Health Organization ( WHO ) classification of myeloid neoplasms and acute leukemia: rationale and important changes [J]. Blood,2009,114 (5): 937-951.
  • 5Cornelissen J J, van Putten W L, Verdonek L F, et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identieal sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle -aged adults: benefits for whom? [J]. Blood, 2007, 109(9) : 3658-3666.
  • 6Dohner H, Estey E H, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults : recommendations from an international expert panel, on behalf of the European LeukemiaNet [J]. Blood, 2010, 115(3): 453-4574.
  • 7Krauter J, Wagner K, Schafer 1, et al. Prognostic factors in adult patients up to 60 years old with acute myeloid leukemia and translocations of chromosome band I lq23: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup[J]. J Clin Oncol, 2009,27 (18) : 3000-3006.
  • 8Medeiros B C, Othus M, Fang M, et al. Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience [Jl. Blood, 2010,116 (13):2224- 2228.
  • 9Breems D A, Lowenberg B. Acute myeloid leukemia with monosomal karyotype at the far end of the unfavorable prognostic spectrum [Jl. Haematologica, 2011,96 (4): 491- 493.
  • 10Iwanaga E, Nanri T, Matsuno N, et al. A JAK2-V617F activating mutation in addition to KIT and FLT3 mutations is associated with clinical outcome in patients with t(8;21) (q22;q22) acute myeloid leukemia [J]. Haematologica, 2009,94(3) : 433-435.

共引文献99

同被引文献60

引证文献7

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部